LRMR: SEC Form 10-Q filed by Larimar Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for LRMR
Across the 8 sessions after earlier LRMR headlines, the stock closed higher 2 times and lower 6 times, with a median move of 4.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LRMR | SPY |
|---|---|---|---|
| May 14, 2026 | Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update | -5.1% | +0.8% |
| May 1, 2026 | Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia | -3.0% | +0.3% |
| Mar 19, 2026 | Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | +4.0% | -0.2% |
| Mar 5, 2026 | Larimar Therapeutics to Participate in Upcoming Investor Conferences in March | -4.2% | -0.6% |
| Feb 26, 2026 | Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offeringand 1 other headline that session | -7.2% | -0.6% |
| Feb 24, 2026 | Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 | +31.3% | +0.7% |
Quantisnow market dataNASDAQ
LRMR
Larimar Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for LRMR
Full LRMR profile on Quantisnow Follow LRMR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time